On October 11, the recall was classified as a class II recall by the FDA—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health ...
The U.S. Food and Drug Administration in 2019 approved intranasal esketamine to treat depression in adults. However, little data is available on the use of ketamine or esketamine to treat bipolar ...